A study of lung cancer patients undergoing radical resections demonstrated that dexmedetomidine reduced the inflammatory response and oxidative stress response, evidenced by lower IL-6, IL-8, and malondialdehyde levels, and higher superoxide dismutase levels compared to controls (129). The gene discussed is IL6; the disease is lung cancer.